These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

481 related items for PubMed ID: 15566669

  • 1. [Relationship between dihydropyrimidine dehydrogenase(DPD) activity and toxicity of 5-FU-based adjuvant chemotherapy in colorectal cancer patients].
    Zhou ZW, Wang GQ, Wan DS, Pan ZZ, Li S, Chen G, Liao H.
    Ai Zheng; 2004 Nov; 23(11 Suppl):1512-6. PubMed ID: 15566669
    [Abstract] [Full Text] [Related]

  • 2. [Relationship of serum level of dihydropyrimidine dehydrogenase and serum concentration of 5-fluorouracil to treatment response and adverse events in colorectal cancer patients].
    Dong QM, He YJ, Li S, Zhou ZM, Zhang L, Zhou ZW, Xia ZJ, Li YY.
    Ai Zheng; 2005 Apr; 24(4):483-7. PubMed ID: 15820075
    [Abstract] [Full Text] [Related]

  • 3. [Correlative analysis between serum dihydropyrimidine dehydrogenase, activity, concentration of 5-fluorouracil and adverse events in the treatment of advanced gastric cancer patients].
    Peng RJ, Dong QM, Shi YX, Cao Y, Zhou ZM, Yuan ZY, Li S, Li H, Jiang WQ.
    Ai Zheng; 2006 Aug; 25(8):1039-43. PubMed ID: 16965690
    [Abstract] [Full Text] [Related]

  • 4. The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients.
    Zhou ZW, Wang GQ, Wan de S, Lu ZH, Chen YB, Li S, Chen G, Pan ZZ.
    Chemotherapy; 2007 Aug; 53(2):127-31. PubMed ID: 17308379
    [Abstract] [Full Text] [Related]

  • 5. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
    Bocci G, Barbara C, Vannozzi F, Di Paolo A, Melosi A, Barsanti G, Allegrini G, Falcone A, Del Tacca M, Danesi R.
    Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
    [Abstract] [Full Text] [Related]

  • 6. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
    Kralovánszky J, Adleff V, Hitre E, Pap E, Réti A, Komlósi V, Budai B.
    Magy Onkol; 2007 Oct; 51(2):113-25. PubMed ID: 17660867
    [Abstract] [Full Text] [Related]

  • 7. A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity.
    Ciccolini J, Mercier C, Blachon MF, Favre R, Durand A, Lacarelle B.
    J Clin Pharm Ther; 2004 Aug; 29(4):307-15. PubMed ID: 15271097
    [Abstract] [Full Text] [Related]

  • 8. Impact of two weekly schedules of oral eniluracil given with fluorouracil and leucovorin on the duration of dihydropyrimidine dehydrogenase inhibition.
    Keith B, Guo XD, Zentko S, Harold N, Schuler B, Quinn M, Shapiro J, Grem JL.
    Clin Cancer Res; 2002 May; 8(5):1045-50. PubMed ID: 12006517
    [Abstract] [Full Text] [Related]

  • 9. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M, Quirino M, Schinzari G, Zannoni G, Corsi DC, Vecchio FM, Cassano A, La Torre G, Barone C.
    Oncology; 2006 May; 70(5):366-77. PubMed ID: 17179731
    [Abstract] [Full Text] [Related]

  • 10. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Kornmann M, Schwabe W, Sander S, Kron M, Sträter J, Polat S, Kettner E, Weiser HF, Baumann W, Schramm H, Häusler P, Ott K, Behnke D, Staib L, Beger HG, Link KH.
    Clin Cancer Res; 2003 Sep 15; 9(11):4116-24. PubMed ID: 14519634
    [Abstract] [Full Text] [Related]

  • 11. [Tumoral dihydropyrimidine dehydrogenase expression and efficacy of 5-fluorouracil plus leucovorin plus UFT therapy in patients with colorectal cancer].
    Ishida H, Ohsawa T, Nakada H, Yokoyama M, Inokuma S, Shirakawa K, Yamada H, Hashimoto D.
    Gan To Kagaku Ryoho; 2004 Jun 15; 31(6):883-7. PubMed ID: 15222105
    [Abstract] [Full Text] [Related]

  • 12. [Expression of mRNA levels of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase of colorectal cancer--relationships among mRNA levels in association with response to 5-FU based treatment].
    Ishida H, Shirakawa K, Ohsawa T, Sobajima J, Hayashi Y, Nakada H, Yokoyama M, Hashimoto D.
    Gan To Kagaku Ryoho; 2005 Nov 15; 32(12):1929-34. PubMed ID: 16282729
    [Abstract] [Full Text] [Related]

  • 13. Tumor dihydropyrimidine dehydrogenase expression is a useful marker in adjuvant therapy with oral fluoropyrimidines after curative resection of colorectal cancer.
    Tsuji T, Sawai T, Takeshita H, Nakagoe T, Hidaka S, Yamaguchi H, Yasutake T, Nagayasu T, Tagawa Y.
    Cancer Chemother Pharmacol; 2004 Dec 15; 54(6):531-6. PubMed ID: 15309506
    [Abstract] [Full Text] [Related]

  • 14. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls.
    Raida M, Schwabe W, Häusler P, Van Kuilenburg AB, Van Gennip AH, Behnke D, Höffken K.
    Clin Cancer Res; 2001 Sep 15; 7(9):2832-9. PubMed ID: 11555601
    [Abstract] [Full Text] [Related]

  • 15. Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy.
    Wettergren Y, Carlsson G, Odin E, Gustavsson B.
    Cancer; 2012 Jun 01; 118(11):2935-43. PubMed ID: 22020693
    [Abstract] [Full Text] [Related]

  • 16. Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients.
    Bocci G, Danesi R, Di Paolo AD, Innocenti F, Allegrini G, Falcone A, Melosi A, Battistoni M, Barsanti G, Conte PF, Del Tacca M.
    Clin Cancer Res; 2000 Aug 01; 6(8):3032-7. PubMed ID: 10955781
    [Abstract] [Full Text] [Related]

  • 17. Thymidylate synthase and dihydropyrimidine dehydrogenase are related to histological effects of 5-fluorouracil and cisplatin neoadjuvant chemotherapy for primary gastric cancer patients.
    Fukuda H, Takiguchi N, Koda K, Oda K, Seike K, Miyazaki M.
    Cancer Invest; 2006 Aug 01; 24(3):235-41. PubMed ID: 16809149
    [Abstract] [Full Text] [Related]

  • 18. Differential effects of two fluorouracil administration regimens for colorectal cancer.
    Matsusaka S, Yamasaki H, Kitayama Y, Okada T, Maeda S.
    Oncol Rep; 2003 Aug 01; 10(1):109-13. PubMed ID: 12469154
    [Abstract] [Full Text] [Related]

  • 19. The role of IVS14+1 G > A genotype detection in the dihydropyrimidine dehydrogenase gene and pharmacokinetic monitoring of 5-fluorouracil in the individualized adjustment of 5-fluorouracil for patients with local advanced and metastatic colorectal cancer: a preliminary report.
    Cai X, Fang JM, Xue P, Song WF, Hu J, Gu HL, Yang HY, Wang LW.
    Eur Rev Med Pharmacol Sci; 2014 Aug 01; 18(8):1247-58. PubMed ID: 24817302
    [Abstract] [Full Text] [Related]

  • 20. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer.
    Poplin EA, Benedetti JK, Estes NC, Haller DG, Mayer RJ, Goldberg RM, Weiss GR, Rivkin SE, Macdonald JS.
    J Clin Oncol; 2005 Mar 20; 23(9):1819-25. PubMed ID: 15774775
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.